Apolipoproteins A1, B, and other prognostic biochemical cardiovascular risk factors in patients with beta-thalassemia major

References

• Finotti A, Gambari R. Recent trends for novel options in experimental biological therapy of beta-thalassemia. Expert Opin Biol Ther. 2014;14(10):1443–54. doi: 10.1517/14712598.2014.927434
   PubMed Web of Science ®Google Scholar
• Ehteram H, Bavarsad MS, Mokhtari M, Saki N, Soleimani M, Parizadeh SM, et al. Prooxidant–antioxidant balance and hs-CRP in patients with beta-thalassemia major. Clin Lab. 2014;60(2):207–15.
   PubMed Web of Science ®Google Scholar
• Bakr A, Al-Tonbary Y, Osman G, El-Ashry R. Renal complications of beta-thalassemia major in children. Am J Blood Res. 2014;4(1):1–6.
   PubMedGoogle Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–73. doi: 10.1056/NEJM199409013310902
   PubMed Web of Science ®Google Scholar
• Shahramian I, Razzaghian M, Ramazani AA, Ahmadi GA, Noori NM, Rezaee AR. The correlation between troponin and ferritin serum levels in the patients with major beta-thalassemia. Int Cardiovasc Res J. 2013;7(2):51–5.
   PubMedGoogle Scholar
• Atefi A, Binesh F, Hashemi A, Atefi A, Aminorroaya M. Seroprovalence of herpes simplex1, 2 IgG antibodies in patients with beta thalassemia in a major tertiary care hospital located in Yazd, Iran. Iran J Ped Hematol Oncol. 2014;4(2):64–7.
   PubMedGoogle Scholar
• Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011:443–50. doi:10.1182/asheducation-2011.1.443.
   PubMed Web of Science ®Google Scholar
• Ohman M, Ohman ML, Wallberg-Jonsson S. The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis. Scand J Rheumatol. 2014;43(4):259–64. doi: 10.3109/03009742.2013.877158
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012;223(1):1–68. doi: 10.1016/j.atherosclerosis.2012.05.007
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298(7):776–85. doi: 10.1001/jama.298.7.776
   PubMed Web of Science ®Google Scholar
• Xu W, Li R, Zhang S, Gong L, Wang Z, Ren W, et al. The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China. Endocrine 2012;42(1):132–8. doi: 10.1007/s12020-012-9599-x
   PubMed Web of Science ®Google Scholar
• Faraj M, Messier L, Bastard JP, Tardif A, Godbout A, Prud'homme D, et al. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 2006;49(7):1637–46. doi: 10.1007/s00125-006-0259-7
   PubMed Web of Science ®Google Scholar
• Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl.) 2006;84(4):276–94. doi: 10.1007/s00109-005-0030-4
   PubMed Web of Science ®Google Scholar
• Savas Erdeve S, Simsek E, Dallar Y, Biyikli Z. Utility of ApoB/ApoA1 ratio for the prediction of cardiovascular risk in children with metabolic syndrome. Indian J Pediatr. 2010;77(11):1261–5. doi: 10.1007/s12098-010-0217-8
   PubMed Web of Science ®Google Scholar
• Lu M, Lu Q, Zhang Y, Tian G. Apob/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. J Biomed Res. 2011;25(4):266–73.
   PubMedGoogle Scholar
• Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK, 3rd, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001;97(8):2381–9. doi: 10.1182/blood.V97.8.2381
   PubMed Web of Science ®Google Scholar
• Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev. 2002;1(1–2):111–7. doi: 10.1016/S1568-9972(01)00018-0
   PubMedGoogle Scholar
• Marti-Carvajal AJ, Sola I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev.1:CD006612.
   Google Scholar
• Ajabnoor MA, MN AL-A, Banjar Z, Rafee AA, Sheweita SA. Homocysteine level and other biochemical parameters in cardiovascular disease patients with diabetes mellitus. Med Sci Monit. 2003;9(12):CR523–7.
   PubMedGoogle Scholar
• Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. JAMA 1997;277(22):1775–81. doi: 10.1001/jama.1997.03540460039030
   PubMed Web of Science ®Google Scholar
• El Oudi M, Aouni Z, Mazigh C, Machghoul S. Total homocysteine levels and cardiovascular risk factors in healthy Tunisians. East Mediterr Health J. 2011;17(12):937–42.
   PubMedGoogle Scholar
• Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003;36(6):431–41. doi: 10.1016/S0009-9120(03)00062-6
   PubMed Web of Science ®Google Scholar
• Alamdari DH, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G. A novel assay for the evaluation of the prooxidant–antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem. 2007;40(3–4):248–54. doi: 10.1016/j.clinbiochem.2006.10.017
   PubMed Web of Science ®Google Scholar
• Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of beta-thalassemias and hemoglobin E disorders. Expert Rev Hematol. 2010;3(1):103–17. doi: 10.1586/ehm.09.74
   PubMed Web of Science ®Google Scholar
• Cighetti G, Duca L, Bortone L, Sala S, Nava I, Fiorelli G, et al. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest. 2002;32(Suppl 1):55–60. doi: 10.1046/j.1365-2362.2002.0320s1055.x
   PubMed Web of Science ®Google Scholar
• Bayar N, Kurtoglu E, Arslan S, et al. Assessment of the relationship between fragmented QRS and cardiac iron overload in patients with beta-thalassemia major. Anadolu Kardiyol Derg. April 2.
   Google Scholar
• Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med. 2001;111(5):349–54. doi: 10.1016/S0002-9343(01)00879-8
   PubMed Web of Science ®Google Scholar
• Kang JY, Park IK, Lee JY, Sung SH, Chang YK, Park YK, et al. Use of serum homocysteine to predict cardiovascular disease in Korean men with or without metabolic syndrome. J Korean Med Sci. 2012;27(5):500–5. doi: 10.3346/jkms.2012.27.5.500
   PubMed Web of Science ®Google Scholar
• Hamer M, Stamatakis E. Physical activity and risk of cardiovascular disease events: inflammatory and metabolic mechanisms. Med Sci Sports Exerc. 2009;41(6):1206–11. doi: 10.1249/MSS.0b013e3181971247
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Crea F, Davignon J, Kaski JC, Koenig W, Landmesser U, et al. Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. J Intern Med. 2007;261(3):214–34. doi: 10.1111/j.1365-2796.2006.01734.x
   PubMed Web of Science ®Google Scholar
• Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J. 2009;30(6):710–7. doi: 10.1093/eurheartj/ehn347
   PubMed Web of Science ®Google Scholar
• Madani H, Rahimi Z, Manavi-Shad M, Mozafari H, Akramipour R, Vaisi-Raygani A, et al. Plasma lipids and lipoproteins in children and young adults with major beta-thalassemia from western Iran: influence of genotype. Mol Biol Rep. 2011;38(4):2573–8. doi: 10.1007/s11033-010-0397-3
   PubMed Web of Science ®Google Scholar
• Papanastasiou DA, Siorokou T, Haliotis FA. Beta-Thalassaemia and factors affecting the metabolism of lipids and lipoproteins. Haematologia (Budap.) 1996;27(3):143–53.
   PubMedGoogle Scholar
• Bordbar M, Haghpanah S, Afrasiabi A, Dehbozorgian J, Karimi M. Genotype–phenotype correlation related to lipid profile in beta-thalassemia major and intermedia in southern Iran. J Clin Lipidol. 2012;6(2):108–13. doi: 10.1016/j.jacl.2011.12.005
   PubMed Web of Science ®Google Scholar
• Al-Quobaili FA, Abou Asali IE. Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major. Saudi Med J. 2004;25(7):871–5.
   PubMed Web of Science ®Google Scholar
• Maioli M, Cuccuru GB, Pranzetti P, Pacifico A, Cherchi GM. Plasma lipids and lipoproteins pattern in beta-thalassemia major. Acta Haematol. 1984;71(2):106–10. doi: 10.1159/000206566
   PubMed Web of Science ®Google Scholar
• Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol. 2008;28(11):1890–1. doi: 10.1161/ATVBAHA.108.173575
   PubMed Web of Science ®Google Scholar
• Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29(8):439–93.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–65. doi: 10.1056/NEJMoa021993
   PubMed Web of Science ®Google Scholar
• Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349(9050):462–6. doi: 10.1016/S0140-6736(96)07591-5
   PubMed Web of Science ®Google Scholar
• Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135(2):254–63. doi: 10.1111/j.1365-2141.2006.06277.x
   PubMed Web of Science ®Google Scholar
• Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, et al. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 2008;93(6):817–25. doi: 10.3324/haematol.11755
   PubMed Web of Science ®Google Scholar
• Ghahremanlu E, Banihashem A, Saber H, Tavallaie S, Mirhosseini N, Ghayour-Mobarhan M, et al. Increased serum heat shock protein 27 antibody titers and prooxidant–antioxidant balance in patients with beta-thalassemia major. Acta Haematol. 2013;129(1):1–9. doi: 10.1159/000339502
   PubMed Web of Science ®Google Scholar
• Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274(13):1049–57. doi: 10.1001/jama.1995.03530130055028
   PubMed Web of Science ®Google Scholar
• Real JT, Martinez-Hervas S, Garcia-Garcia AB, Chaves FJ, Civera M, Ascaso JF, et al. Association of C677 T polymorphism in MTHFR gene, high homocysteine and low HDL cholesterol plasma values in heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2009;16(6):815–20. doi: 10.5551/jat.2196
   PubMed Web of Science ®Google Scholar
• Veerkamp MJ, de Graaf J, den Heijer M, Blom HJ, Stalenhoef AF. Plasma homocysteine in subjects with familial combined hyperlipidemia. Atherosclerosis 2003;166(1):111–7. doi: 10.1016/S0021-9150(02)00312-X
   PubMed Web of Science ®Google Scholar
• Ozdem S, Kupesiz A, Yesilipek A. Plasma homocysteine levels in patients with beta-thalassaemia major. Scand J Clin Lab Invest. 2008;68(2):134–9. doi: 10.1080/00365510701516343
   PubMed Web of Science ®Google Scholar
• Sherief LM, Abd El-Salam SM, Kamal NM, El Safy O, Almalky MA, Azab SF, et al. Nutritional biomarkers in children and adolescents with beta-thalassemia-major: an Egyptian center experience. Biomed Res Int. 2014:261761, doi:10.1155/2014/261761. Epub 2014 Apr 8.
   PubMed Web of Science ®Google Scholar